Firm expands its CNS pipeline.

A drug technology to treat Alzheimer’s disease developed by a team of researchers at the George S. Wise Faculty of Life Sciences at Tel Aviv University (TAU) was licensed to Merz Pharmaceuticals.

The technology developed at TAU was one of a portfolio of technologies that were selected to be funded by an $8.5M investment raised by Ramot, the university’s tech transfer office, in 2003 from a group of U.S investors. 

“Our goal is to offer novel therapeutic options to patients by developing innovative new drugs within our main area of expertise, the treatment of CNS disorders,” says Alexander Gebauer, head of global R&D at Merz Pharmaceuticals.

The worldwide, exclusive rights include an upfront fee, milestone payments and royalties.

Previous articleResearchers Find Clues to the Causes of APL
Next articleOncoMethylome Enhances Pharmacogenomic Services in Deal with BioTrove